Pediatric Multiple Sclerosis: Diagnosis, Treatment, and Outlook

Staff
By Staff
4 Min Read
To date, there’s only one disease-modifying therapy (DMT) approved in the United States for use in children with MS: the oral drug fingolimod (Gilenya).
The U.S. Food and Drug Administration (FDA) has approved its use for treating pediatric MS in children and adolescents age 10 or older.
In MS, which is an autoimmune condition, your immune system mistakenly attacks the nerve cells in your CNS. Fingolimod is an immunosuppressant that is thought to work by keeping your body’s immune cells in your lymph nodes, where they can’t attack the CNS.

Off-label Use of DMTs for Pediatric MS

Oral DMTs used off-label in children with relapsing-remitting MS include:
  • dimethyl fumarate (Tecfidera)
  • teriflunomide (Aubagio)
  • alemtuzumab (Lemtrada)
  • natalizumab (Tysabri)
  • rituximab (Rituxan)
  • glatiramer acetate (Copaxone)
  • interferon beta (Avonex, Rebif, Plegridy)
Some of these drugs are currently being evaluated in clinical trials involving pediatric patients with the condition, and some are already approved in other countries outside the United States.

Options for Treating MS Relapses

During MS flares, high-dose corticosteroids may be prescribed to reduce inflammation in the CNS. The most commonly used corticosteroid in children with MS is methylprednisolone, which is administered intravenously once a day for three to five days.
Your child’s doctor may also prescribe prednisone, another corticosteroid, which is available in pill form. It’s typically used for a short time following IV methylprednisolone administration.

Although most children generally tolerate corticosteroids well, they may experience some side effects, such as:

  • Behavior changes
  • Increases in blood sugar levels
  • Nausea

Other options for treating relapse include plasma exchange and intravenous immunoglobulin (IVIG). Plasma exchange, also called plasmapheresis or PLEX, essentially removes the antibodies in the blood that attack myelin in the nerve cells of people with MS. Several treatments are given over a couple of weeks.

IVIG is an IV medication composed of antibodies from healthy blood donors and helps reduce the immune response in MS. IVIG is not typically the first treatment used for an MS relapse but may be used in certain situations.

Additional Parts of the MS Treatment Plan

Any treatment plan for children with MS should also include:

  • Physical therapy
  • Occupational therapy
  • Speech therapy

These can help improve mobility, muscle strength, and balance and coordination.

It’s important to remember that children diagnosed with MS can experience emotional and social challenges. Having a chronic condition like MS can affect a young person’s self-confidence, academic performance, peer relationships, family and social life, and overall behavior.

It may also impact how they view their lives, both in the present and in the future.

Thus, Krupp says, it’s vital that children with MS communicate regularly with school counselors, therapists, and others who can help them with these challenges. Encourage them to talk about their experiences and problems, and make sure they get support from teachers, family, friends, and other members of the community.

“A team that provides counseling, ideally peer-based support programs, is key,” she says.

Yeh adds that a comprehensive program should address all the needs of children with MS, and ideally should include physicians, nurses, nurse practitioners, social workers, psychologists, neuropsychological assessment, and physiotherapists and occupational therapists, among other healthcare workers.

Ultimately, planning your child’s MS treatment should include discussing the goals and expectations of the child and the family, as well as any potential risks. Children on DMTs and other prescription medication should also undergo routine monitoring (including blood tests, MRIs, and other tests) to make sure the treatment is working and to minimize side effects.

Read the full article here

Share This Article
Leave a comment

Leave a Reply

Your email address will not be published. Required fields are marked *